FDA warns Jubilant tablet plant in India for repeat mistakes

Pills in dollar sign (Photo: Eric Palmer)
Jubilant Life Sciences has been slapped by the FDA with a warning letter for one of its 14 plants in India. (Eric Palmer)

The FDA has picked apart the process of a Jubilant solid-dose plant in India and criticized it for repeating mistakes it had been told about in the past.

In a warning letter issued a week ago and just posted, the FDA said the Jubilant Life Sciences plant in Sikanderpur Bhainswal, Uttarakhand, had not thoroughly investigated customer complaints and that its quality-control lab was not testing every batch of a product when one batch failed testing, something management had previously committed to doing.

In one example, the letter said that the facility had received “numerous complaints for damage to functional coating on pantoprazole delayed release tablets” which could affect dissolution. Its investigation, however, tested tablets with discoloration instead of testing those with considerable enteric coating damage that were more likely to fail.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate,” the agency said, suggesting the company hire an outside consultant for help.

RELATED: India's Jubilant Life Sciences turns a manufacturing corner

These kinds of concerns are not new to the Indian company. Its sterile injectables plants in Spokane, Washington, and Kirkland, Canada, were cited with warning letters in 2013. The investigation of the Quebec plant was closed out the next year.

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.